BLFS vs. BLCO, INSP, SLNO, PRCT, NVST, LIVN, WRBY, NVCR, LMAT, and ENOV
Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Soleno Therapeutics (SLNO), PROCEPT BioRobotics (PRCT), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), and Enovis (ENOV). These companies are all part of the "medical equipment" industry.
BioLife Solutions vs. Its Competitors
BioLife Solutions (NASDAQ:BLFS) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Comparatively, 0.8% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
BioLife Solutions currently has a consensus target price of $31.17, indicating a potential upside of 31.28%. Bausch + Lomb has a consensus target price of $15.54, indicating a potential upside of 24.09%. Given BioLife Solutions' stronger consensus rating and higher possible upside, equities analysts plainly believe BioLife Solutions is more favorable than Bausch + Lomb.
BioLife Solutions received 272 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 66.74% of users gave BioLife Solutions an outperform vote while only 40.59% of users gave Bausch + Lomb an outperform vote.
BioLife Solutions has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
Bausch + Lomb has a net margin of -6.62% compared to BioLife Solutions' net margin of -38.98%. Bausch + Lomb's return on equity of 3.35% beat BioLife Solutions' return on equity.
In the previous week, Bausch + Lomb had 8 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for Bausch + Lomb and 2 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.35 beat Bausch + Lomb's score of 0.14 indicating that BioLife Solutions is being referred to more favorably in the media.
BioLife Solutions has higher earnings, but lower revenue than Bausch + Lomb. BioLife Solutions is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.
Summary
BioLife Solutions beats Bausch + Lomb on 12 of the 18 factors compared between the two stocks.
Get BioLife Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLife Solutions Competitors List
Related Companies and Tools
This page (NASDAQ:BLFS) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy BLFS Stock Free BLFS Stock Alerts